A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma

被引：0
|
作者：
Apolo, Andrea Borghese
Parnes, Howard L.
Madan, Ravi Amrit
Gulley, James L.
Wright, John Joseph
Khadar, Kattie
Trepel, Jane B.
Schlom, Jeffrey
Arlen, Philip M.
Merino, Maria
Steinberg, Seth M.
Choyke, Peter L.
Lindenberg, Maria Liza
Kurdziel, Karen A.
Folio, Les
Figg, William Douglas
Agarwal, Piyush K.
Bottaro, Donald P.
Dahut, William L.
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] NCI, Canc Prevent Div, Bethesda, MD 20892 USA
[3] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA
[4] NCI, Rockville, MD USA
[5] NCI, Med Oncol Branch, Bethesda, MD 20892 USA
[6] NCI, Lab Tumor Immunol & Biol, Med Oncol Branch, Bethesda, MD 20892 USA
[7] NCI, NIH, Bethesda, MD 20892 USA
[8] NCI, Biostat & Data Management Sect, CCR, Bethesda, MD 20892 USA
[9] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[10] NCI, Mol Imaging Program, CCR, NIH, Bethesda, MD 20892 USA
[11] NIH, Bethesda, MD 20892 USA
[12] NCI, Mol Pharmacol Sect, NIH, Bethesda, MD 20892 USA
[13] NCI, Urol Oncol Branchd, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4589
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors.
    Gordon, M. S.
    Vogelzang, N. J.
    Schoffski, P.
    Daud, A.
    Spira, A. I.
    O'Keeffe, B. A.
    Rafferty, T.
    Lee, Y.
    Berger, R.
    Shapiro, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models
    Sameni, Mansoureh
    Tovar, Elizabeth A.
    Essenburg, Curt J.
    Chalasani, Anita
    Linklater, Erik S.
    Borgman, Andrew
    Cherba, David M.
    Anbalagan, Arulselvi
    Winn, Mary E.
    Graveel, Carrie R.
    Sloane, Bonnie F.
    CLINICAL CANCER RESEARCH, 2016, 22 (04) : 923 - 934
  • [33] Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
    Kurzrock, Razelle
    Sherman, Steven I.
    Ball, Douglas W.
    Forastiere, Arlene A.
    Cohen, Roger B.
    Mehra, Ranee
    Pfister, David G.
    Cohen, Ezra E. W.
    Janisch, Linda
    Nauling, Forlisa
    Hong, David S.
    Ng, Chaan S.
    Ye, Lei
    Gagel, Robert F.
    Frye, John
    Mueller, Thomas
    Ratain, Mark J.
    Salgia, Ravi
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (19) : 2660 - 2666
  • [34] Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC)
    Cabanillas, Maria E.
    Brose, Marcia S.
    Ramies, David A.
    Lee, Yihua
    Miles, Dale
    Sherman, Steven I.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse
    De Groot, J. F.
    Prados, M.
    Urquhart, T.
    Robertson, S.
    Yaron, Y.
    Sorensen, A. G.
    Norton, A.
    Batchelor, T.
    Drappatz, J.
    Wen, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Phase 2 study of XL184 (BMS-907351) in a cohort of patients (pts) with hepatocellular carcinoma (HCC)
    Van Cutsem, E.
    Su, W. C.
    Davis, J.
    Haas, N.
    Samuel, T. A.
    Tsao, C. J.
    Yang, T. S.
    Brandy, H.
    Mann, G.
    Cohn, A.
    EJC SUPPLEMENTS, 2010, 8 (07): : 129 - 130
  • [37] Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE)
    Smith, Matthew Raymond
    Sweeney, Christopher
    Rathkopf, Dana E.
    Scher, Howard I.
    Logothetis, Christopher
    George, Daniel J.
    Higano, Celestia S.
    Yu, Evan Y.
    Harzstark, Andrea Lynne
    Small, Eric Jay
    Sartor, A. Oliver
    Gordon, Michael S.
    Vogelzang, Nicholas J.
    Smith, David C.
    Hussain, Maha
    De Bono, Johann Sebastian
    Haas, Naomi B.
    Scheffold, Christian
    Lee, Yihua
    Corn, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Cabozantinib (XL184) inhibits prostate tumor growth and bone lesion development
    Dai, Jinlu
    Zhang, Honglai
    Karatsinides, Andreas
    Aftab, Dana
    Schimmoller, Frauke
    Keller, Evan T.
    CANCER RESEARCH, 2012, 72
  • [39] Phase 2 randomized discontinuation trial (RDT) of XL184 in patients (pts) with advanced solid tumors
    Schoeffski, P.
    Sgroi, M.
    Burris, H. A.
    Lutzky, J.
    Rearden, T.
    Sikic, B.
    Stephenson, J., Jr.
    Elhardt, D.
    Lee, Y.
    Kurzrock, R.
    EJC SUPPLEMENTS, 2010, 8 (07): : 117 - 117
  • [40] Anti-tumor activity observed in an ongoing phase 1 drug-drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma
    Choueiri, T. K.
    Pal, S. K.
    McDermott, D. M.
    Ramies, D. A.
    Morrissey, S.
    Lee, Y.
    Miles, D.
    Holland, J. S.
    Dutcher, J. P.
    BJU INTERNATIONAL, 2012, 109 : 4 - 4
12345